髓系白血病
癌症研究
疾病
医学
白血病
动力学
髓样
免疫学
微小残留病
突变
残余物
生物
癌症
癌症的体细胞进化
化学
作者
Shrinidhi Nathany,Moin Makda,Hrithik Bagga,Haristuti Verma,Anusha Swaminathan,Swarsat Kaushik Nath,Nikhil M Kumar,Siddharth Sagar,A. K. Gupta,Surbhi Singh,Kanika Verma,Devyani Surange,Mehak Trehan,Sunisha Arora,Vikas Dua,Bhargava Rahul
出处
期刊:
[Elsevier BV]
日期:2026-08-19
卷期号:2 (4): 100150-100150
标识
DOI:10.1016/j.bglo.2026.100150
摘要
Measurable residual disease (MRD) in acute myeloid leukemia (AML) is commonly reported as a binary variable, which may not capture the biological heterogeneity of residual disease in resource-constrained settings such as India, particularly in patients with multiple co-occurring mutations.We conducted a prospective, single-centre study at a tertiary haematology and bone-marrow-transplantation centre in northern India. Sixty-nine consecutive newly diagnosed AML patients underwent serial MRD assessment using a duplex UMI-based next-generation sequencing (NGS) assay targeting 33 genes and 43 fusion drivers. Individual mutations were tracked longitudinally across up to 11 serial timepoints. Gene-level clearance kinetics were analysed in relation to functional category, clonal hierarchy inferred from variant allele frequency (VAF), and treatment intensity. A total of 153 evaluable mutations across 59 patients were analysed. While 62.7% of mutations achieved post-induction clearance, only 37.3% of patients achieved complete MRD negativity, reflecting discordant clearance among co-existing clones. Clearance rates varied by functional category: signaling 76.0% and transcription factor 80.6%, compared with 38.2% for epigenetic modifiers and 0% for TP53 . IDH1 /2 mutations showed low early clearance (25.0%) but delayed clearance (63.6%). Founder mutations cleared less frequently than subclonal mutations (53.2% vs. 72.2%; p = 0.037). Joint FCM/NGS categorisation at the first post-induction timepoint stratified 24-month relapse incidence from 8.3% (True Negative) to 37.5% (Occult MRD, FCM−/NGS+) to 60.0% (FCM+/NGS+) (Gray's p = 0.015). MRD in AML comprises heterogeneous, gene-specific clearance trajectories influenced by functional category and clonal architecture. Gene-level kinetics refine MRD interpretation beyond binary assessment.
科研通智能强力驱动
Strongly Powered by AbleSci AI